written on 23.04.2014

Amgen's $4.5B in Q1 sales lags estimates, thanks to slow-selling Enbrel


Amgen reported a mixed bag of results in the first earnings period following its acquisition of Onyx Pharmaceuticals. First-quarter revenues came in approximately $230 million lower than consensus, a miss that the company attributes primarily to sluggish sales of Enbrel.